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Comparative genomic hybridization (CGH) studies have demon-
strated a high incidence of chromosomal imbalances in non-
Hodgkin’s lymphoma. However, the information on the genomic
imbalances in Burkitt’s Lymphoma (BL) is scanty. Conventional
cytogenetics was performed in 34 cases, and long-distance
PCR for t(8;14) was performed in 18 cases. A total of 170
changes were present with a median of four changes per case
(range 1–22). Gains of chromosomal material (143) were more
frequent than amplifications (5) or losses (22). The most
frequent aberrations were gains on chromosomes 12q (26%),
Xq (22%), 22q (20%), 20q (17%) and 9q (15%). Losses
predominantly involved chromosomes 13q (17%) and 4q (9%).
High-level amplifications were present in the regions 1q23–31
(three cases), 6p12–p25 and 8p22–p23. Upon comparing BL vs
Burkitt’s cell leukemia (BCL), the latter had more changes
(mean 4.372.2) than BL (mean 2.773.2). In addition, BCL cases
showed more frequently gains on 8q, 9q, 14q, 20q, and 20q, 9q,
8q and 14q, as well as losses on 13q and 4q. Concerning
outcome, the presence of abnormalities on 1q (ascertained
either by cytogenetics or by CGH), and imbalances on 7q
(P¼0.01) were associated with a short survival.
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Introduction
Burkitt’s lymphomas (BLs) comprise a heterogeneous group of
highly aggressive B-cell malignancies.1 Recently, the World
Health Organization (WHO) classification has included the L3
variant of acute lymphoblastic leukemia (ALL) as equivalent to
BL in leukemic phase or Burkitt’s cell leukemia (BCL).2 All cases
of BL share a common genetic lesion, characterized by a reci-
procal chromosomal translocation involving the c-MYC gene on
chromosome 8q24 and one of the immunoglobulin (Ig) genes
located on chromosome 14q32 (Ig heavy chain, IgH), chromo-
some 2p12 (Ig kappa, Igk) or chromosome 22q11 (Ig lambda,
Igl). All 8q24 breaks lead to a deregulation of the c-MYC proto-
oncogene. Over the last 10 years, several cytogenetic reports
have suggested that so-called ‘secondary’ chromosome changes
could influence the clinical picture of lymphoid tumors.3,4 Most
of the secondary chromosome changes are unbalanced re-
arrangements, leading to DNA gains or losses.5 The develop-
ment of molecular cytogenetics techniques, allowed for a
refinement of the cytogenetic profile of NHL. Thus, comparative
genomic hybridization (CGH), provides in a single experiment a
general view of genomic imbalances, including partial or
complete trisomies, monosomies or amplifications within the
tumor genome. This technique can be used to identify pre-
viously unexpected genetic abnormalities. Several groups have
studied chromosomal changes by CGH in B-cell NHL, such as
mantle cell lymphoma, follicular lymphoma, marginal lympho-
ma and diffuse large-cell lymphoma.6–11 However, little is
known about the genomic imbalances in BL. The present study
was designed to screen DNA copy changes by CGH in a series
of 46 patients diagnosed as BL or BCL and to correlate the results
obtained from CGH with the most relevant clinical, biological
and cytogenetic characteristics, including disease outcome.
Materials and methods
Patients
A total of 46 patients with histologically and morphologic
confirmed diagnosis of BL were analyzed by CGH. Histopatho-
logic evaluation was performed based on morphologic and
immunohistochemical criteria according to the WHO classifica-
tion of malignant lymphoma by two expert hematopathologists
(TF and MAP).2 The median age was 35 years (range 5–77
years). Most of them were male (74%). In each patient, the
following initial data were recorded and evaluated for prog-
nosis: age, gender, performance status according to the Eastern
Cooperative Oncology Group (ECOG) scale, serum lactate
dehydrogenase (LDH) level, tumor extension, extranodal
involved sites and bone marrow (BM) infiltration. Patients were
treated with chemotherapy-based protocols as BFM, CODOX-
M-IVAC and LSA2-L2 with slight modifications. All samples
were analyzed at diagnosis of the patients.
Cytogenetics
Cytogenetic studies were carried out in 34 patients. Chromo-
some analysis was performed in BM (15 cases), peripheral blood
(six cases), lymph nodes (eight cases) and material with
neoplastic cells (spleen, fluids and tumoral mass) in the
remaining five patients. Cytogenetics was performed after direct
or 24 h culture without stimulating agent according to the
methodology previously reported.12
Comparative genomic hybridization
DNA was extracted from fresh frozen tissue (21 cases), from
archival cells fixed in Carnoy (eight cases), from BM slides (nine
cases) or from paraffin-embedded tissues in the remaining eight
patients. The phenol–chloroform method was used for DNAReceived: 20 February 2003; accepted: 28 May 2003
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extraction according to standard procedure. In cases with a low
yield of extracted DNA, a universal amplification of genomic
DNA with degenerate oligonucleotide primed PCR (DOP-PCR)
was used.13 CGH analysis was performed according to the
method described by Lichter et al.14 Briefly, tumor DNA (test
DNA) was labeled with biotin-16–dUTP (Boehringer Man-
nheim, Mannheim, Germany) and normal DNA (reference
DNA) was labeled with digoxigenin-11–dUTP (Boehringer
Mannheim) by a standard nick-translation reaction. The sizes
of the nick-translated fragments range from 300 to 1000 bp.
Equal amounts (1 mg) of labeled tumor and normal DNAs, and
70mg of unlabeled human Cot-1 DNA (GIBCO/BRL, Gaithers-
burg, MD, USA) were cohybridized to slides with human
metaphase chromosome spread prepared from phytohemagglu-
tinin-stimulated lymphocytes from normal individuals. After
hybridization for 1–2 days in a moist chamber at 371C,
posthybridization washes were performed to a stringency of
0.1 SSC at 421C. Tumor and normal DNA were detected by
avidin–fluorescein isothiocyanate (FITC) and rhodamine-con-
jugated antidigoxigenin, respectively. The slides were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI) and mounted
with an antifade solution. Image acquisition was performed with
an epifluorescence microscope (Nikon MDR1000) equipped
with a cooled charge-coupled device (CCD) camera. The
images were analyzed with Quips CGH software (QUIPS, Vysis,
Downers Grove, IL, USA). Calculation of the tumor DNA to
normal DNA fluorescent ratios along the length of each
chromosome was performed by means of an automated CGH
software package (Quips). Ratio values above 1.25 and below
0.75 were considered to represent chromosomal gains and
losses, respectively. A high-level amplification was considered
when the fluorescence ratio values exceed 1.5. Ratio values
obtained from at least 10 metaphase cells for each case were
averaged. Ratio values above 1.25 and below 0.75 were
considered to represent chromosomal gain and loss, respec-
tively. Over-representations were defined as high-level ampli-
fications when the profiles exceeded the cutoff value of 1.5.
Chromosomal gains exceeding 1.5 involving the whole chro-
mosome or large areas of a chromosomal arm were not
considered as high-level DNA amplification.
Negative control experiments were performed using differen-
tially labeled male vs male DNA, and female vs female DNA.
Additional control experiments included the interchange of the
digoxigenin–dUTP and biotin-dUTP labels between normal and
tumor. According to previous reports, changes on terminal 1p
and chromosome 19 were excluded from the final calculation
because they are known to be critical in CGH.15
Genomic DNA preparation and long distance-PCR
amplification
High-molecular weight DNA was isolated from fresh or frozen
adenopathies and/or bone marrow samples by standard
proteinase-K digestion, phenol–chloroform extraction and etha-
nol precipitation. Based on the structure of the genes involved in
the t(8;14)(q24;q32) translocation and previous data16,17
(Figure 1), we used one MYC-specific primer, recognizing a
region in exon 2, three primers for the constant IgH regions Cm,
Cg and Ca and one for the JH regions. The specificity of this
assay was established by the lack of t(8;14)(q24;q32) specific
PCR product in genomic DNA from healthy individuals
(Figure 2).17 LD-PCR was performed in a 9700 thermal cycler
(Aplied Biosystems, Foster City, CA, USA) using the Expand
Long Template PCR System Kit (Boehringer Mannheim, Man-
nheim, Germany) in 50ml total volume following the manu-
facture’s instructions. For each tube 250 ng genomic DNA was
added, together with 60 pmol of each of the corresponding
primer. The quality of DNA was tested with the tPA control
primer set (Boehringer Mannheim, Mannheim, Germany)
for long amplification. PCR products were analyzed by agarose
gel electrophoresis (0.8% agarose) and ethidium bromide
staining.
Figure 1 LD-PCR analysis of BL/BCL. Amplification of the tPA
control gene. In lane 1 (case 3) there is no amplification of neither of
the two fragments. Lane 2 (case 6) represents a relatively high-quality
DNA sample as we could amplify the 4.5 kb fragment of the tPA gene.
In lane (case 7), we found amplification of both 4.5 and 9 kb fragments
of the tPA gene.
Figure 2 LD-PCR amplification of t(8;14). Patient 20 shows
amplification of the translocation involving c-myc and Cg constant
region. In patient 42, we found amplification of c-myc–JH together
with c-myc–Ca.
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Statistical methods
Differences between groups were compared by the Fischer’s
exact test (two-tailed) and the Student’s test. The actuarial
survival analysis was performed according to the method
described by Kaplan and Meier18 and the curves were compared
by log-rank test. The univariate analysis was performed for each
of the parameters mentioned earlier. P-values less than 0.05
were considered to indicate statistical significance. Data were
analyzed with SPSS statistical software (SPSS Inc., Chicago, IL,
USA). The incidence of clinical features among subgroups was
analyzed with the Pearson w2 test.
Results
Clinical characteristics
The most relevant demographic and clinical characteristics are
shown in Table 1. A high proportion of patients had extranodal
involvement (74%), and approximately half of them showed
bulky disease (44%) high serum LDH levels, more than 1000 IU
(46%) or advanced performance status (50%). The overall
survival of the whole series was 777 months. At the time of the
analysis 27 patients (59%) died. The median survival for patients
with diagnosis of BL was 25 months (range: 52–136), while the
patients with BCL had a median survival of only 6 months
(range: 0–12 months).
Cytogenetic analysis
Cytogenetic results are shown in Table 2. In 85% of the cases,
chromosomal abnormalities were found and, most of them (24
out of 26) showed pseudodiploid karyotypes. Five cases (case
nos. 2, 20, 22, 34 and 40) had a composite karyotype (more than
two chromosomal abnormalities). A t(8;14) translocation was
present in 76% of patients, while the variant translocations
t(8,22) and t(2;8) affected 21 and 3% of cases, respectively. The
most frequent secondary cytogenetic abnormalities were
changes in 1q (29%), partial trisomies of chromosome 1
(10%), changes in 13q (7%) and deletion of 9p (10%), 13q
(7%), 6q and 17p (3% each) (Table 2).
LD-PCR amplification of t(8;14)(q24;q32)
Tumor specimens obtained from 18 unselected BL/BCL were
studied with the four combinations of MYC and IGH primers.
We were able to detect the t(8;14)(q24;q32) in nine out of 18
patients analyzed (50%). Nevertheless, in seven out of the nine
patients in which no LD-PCR product could be detected, we
also failed in the amplification of the tPA control gene,
indicating that poor-quality DNA was obtained. Therefore,
t(8;14)(q24;q32) was detected in nine out of the 11 valuable
patients (81%). In six out of 11 patients (60%) with a
cytogenetically detectable t(8;14)(q24;q32), an LD-PCR translo-
cation product was seen (cases nos: 20, 21, 38, 40, 42 and 45).
Moreover, we could confirm the t(8;14)(q24;q32) by LD-PCR in
another three samples (case nos. 6, 7, and 23, Table 2) in which
cytogenetic data were not available. In three of the 11 cases
showing t(8;14) positive samples (case nos. 7, 21, 42) two
primer combinations showed an LD-PCR product (Table 2).
Comparative genomic hybridization
The distribution of genomic imbalances are shown in Figure 3
and in Table 2. Out of the 46 patients with BL/BCL (76%), 35
showed DNA changes by CGH. A total of 170 DNA copy
number changes were detected with a median of four
abnormalities per case (range: 1–22): 143 gains, 22 losses and
five high-level amplifications (Table 3). Most cases showed
more than one chromosomal imbalance. However, single
alterations were identified in some cases, including one case
with a high-level amplification on 1q (case 20), one patient with
loss on 17p (case 43) as well as cases with gains on 4p, 13q, 7p,
Xq and 2p (case nos. 12, 13, 32, 35 and 36, respectively).
Irrespective of the morphology or clinical characteristics, the
most frequent findings (present in 45% of cases) were gains
involving regions at 12q (26%), Xq (22%), 22q (20%), 20q
(17%), 9q and 8q (15% each), 1q, 4p, 7q, 13q, 10q (13% each)
and 6q and 14q (11% each). The gains of whole chromosome
involved chromosomes 12, 16 and 20 (11% each), as well as 11
and 21 (9%) (Figure 3). The losses were detected on chromo-
somes 13q (17%), 4q (9%) 6q and 17p (4% each). The
commonly affected regions were delineated to 13q14–q31,
4q21–q28 6q21–q23 and 17p13. In five cases, high-level DNA
amplifications were found that mapped on chromosomes band
1q23 to 1q31 (three cases), 6p12–p25 and 8p22–p23 (Figure 3).
Details of the GCH are listed in Table 2, and complete data are
illustrated in Figure 3.
Associations among cytogenetics, histopathologic and
clinical baseline parameters
The comparison between the genomic changes observed in BL
and BCL is summarized in Table 3. Overall, 15 out of the 19
cases of BL (79%) and 20 out of the 27 BCL (74%) had genomic
imbalances. The mean number of chromosome imbalances per
case was more frequent in BCL (mean of 4.372 per case) than in
BL (mean of 2.773 per case), but the differences did not reach
statistical significance. The chromosomal imbalances detected
Table 1 Clinical Characteristics of 46 Patients with BL/BCL
No. %
Age (years)
Median 36
Range (5–77)
o14 years 10 21
Sex
Male 34 74
Female 12 26
Involvement
Lymph node (BL) 19 41
Bone marrow+lymph node (BCL) 16 35
Bone marrow (BCL) 11 24
Extranodal involvementa 34 74
Increased LDH level 41000 IUb 21 46
Performance status (ECOG 42) 23 50
Bulky disease 20 44
t(8;14)c
Present 32 86
Not present 5 13
aIn 26% cases, more than one region was involved.
bAll patients showed an increased amount of LDH.
cTranslocation was analyzed by cytogenetics or LD-PCR in 37 cases.
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Table 2 Cytogenetics, CGH and LD-PCR results in BL/BCL
Ref Histology Cytogenetics CGH LD-PCR
Primary Secondary Gains Losses Amplification LD-PCR result Region
Involved
1 BL t(8;14) 4q26–q28, Xq28–qter 0 0 ND
2 BL t(8;22) dup(1)(q25q32),
add(9)(p23)
10q22–q25 12p11–13 1q22–q25  
3 BL ND 8q24–qter,9q34–qter,
+10,+12,13q32–q34
0 8p11-p23  
4 BL t(8;14) Xq11-q22 0 0 ND
5 BL t(8;22) +7 3q26-q29,7q32-q36,
20q11-q13
0 0  
6 BL NG 7p15-p22,Xp21-p22 0 0 + Ca
7 BL ND +2,7q22-
q36,+12,+21,+22
0 1q21-q25 + ca+cg
8 BL ND 11p14-p15, Xq12-q21 13q13-q21 0  
9 BL NG 4p15-p16,12q22-q24,
17p11-p13
0 0 ND
10 BL ND 1q22-q24,6q25-
q27,7q34–36
Xp11-p22 0 ND
11 BL ND 0 0 0 ND
12 BL NG 4p15-p16 0 0 ND
13 BL ND 13q21-q22 0 0 ND
14 BL ND 0 0 0 ND
15 BL ND 1p11–p22;2q21–q33,
13q21–q22, Xq13–q22
0 0 ND
16 BL NG 0 0 0 ND
17 BL ND 12q22–q24,20,+22 4q21–q27, 13q14–q22 0 ND
18 BL ND 2q14–q32,4q22–
q35,5q13–q21,6q14–
q27,3q22–q33,8q22–
q23
1p32–p36, 17p11–
p13, 20q11–q13
0 + 
19 BL NG 0 0 0 ND
20 BCL t(8;14) add(1)(q41),
+del(1)(p21p32)
0 0 1q21–q25 + Cg
21 BCL t(8;14) 10p11–p13,Xq13–q21 0 0 + cm+cg
22 BCL t(8;14) +del(1)(p13p35),
del(6)(q15q2),
+15,+16,der(19),
t(7;19)(q12;q13)
3q21–q27,6q23–
q27,8q24–
qter,12,+15,Xp11–p22
0 0 ND
23 BCL ND 1q31–q44,5p13–
p15,7q31–q36,12q22–
q24,Xq26–q28
0 6p12–p25 + cg
24 BCL t(8;22) 0 0 0 ND
25 BCL t(8;14) +i(1)(q) +21,+22 13q21–31 0 ND
26 BCL t(8;14) 8q24–qter, xq26–q28 0 0 ND
27 BCL t(2;8) Xp11–p22 13q21–q31 0 ND
28 BCL t(8;14) 9q22–q34, 12q22–
q24, 14q24–q32,
15q22–q26, 17q23–
q25, +20, +22
13q21–q31 ND
29 BCL t(8;22) 22q11–q13, Xq26- q28 0 0 ND
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30 BCL t(8;22) i(1)(q10) 0 0 0 ND
31 BCL t(8;14) 0 0 0 
32 BCL t(8;14) 7p14–p21 0 0 ND
33 BCL t(8;14) dup(1)(q31q42), 0 0 0 ND
34 BCL t(8;14) del(6)(q2?1q23),
del(10)(q22q26),
del(9)(p21p23)
9q22–q34,12p12–
p13,+22
6q15–q25, 13q14–q22 0 ND
35 BCL t(8;22) del(13)(q14q34) Xq24–q26 0 0 ND
36 BCL ND 2q32–q37 0 0 ND
37 BCL t(8;14) 0 0 0 ND
38 BCL t(8;14) 9q33–q34, 12q22–
q24, +16,+17,20q11–
q13, +21
4q21–q27, 13q14–q22 + cm
39 BCL t(8;14) 7q34–q36, 10q23–
q25, +16,17p11–p13,
20q11–q13, +22
0 0 + 
40 BCL t(8;14) add(13)(q34),
add(16)(p13)
4p15–p16, 5q32–q34,
6q24–q27,8q23–
q24,+11, 12q22–
q24,14q32,+16,
+17,20, +22
4q13–q32,13q14–q22 0 + cg
41 BCL t(8;14) add(17)(q25) 0 0 0  
42 BCL t(8;14) del(9)(p13) 0 0 0 + JH+cm
43 BCL t(8;14) del(17)(p11) 0 17p11–p13 0  
44 BCL t(8;14) del(3)(p24) 2p21–p25, 2q35–
q37,4p15–p16, 5p13–
p15, 5q32–q35
0 0 ND
6p21–p25, 6q24–q27,
7q32–q36,8q23–q24,
9q33–q34, 10q25–
q26,+11,+12, 13q32–
q34,14q31–q32,
15q24–q26, +16, +17,
+20, +22
45 BCL t(8;14) dup(1)(q22q31) 1p22–p32, 3p21–p25 0 0 + cm
4p13–p16, 4q21–q31,
7p13–p21, +8, 9q21–
q31, +10, +11, 12q14–
q22, 13q13–q21,
14q21–q31, Xq12–q28
46 BCL t(8;14) der(4)t(1;4)(q21;q32) +1, 2q33–q37, 4p15–
p16,5p13–p15, 8q23–
q24, 9q32–q34,+10,
+11, +12, 13q31–q34,
14q31–q32, 15q22–
q24,+16, +17,
20,+21,+22
4q12–q35, 5q12–q21,
6q12–q21, 7q21–q31
ND
BL, Burkitt’s lymphoma; BCL, Burkitt’s cell leukemia; CGH, comparative genomic hybridization; LD-PCR, long-distance polymerase chain reaction; Cg,Cm, Ca and JH refer to the regions of the IgH
locus (C, constant; J, joining) recognized by the primer that obtained the PCR product; ND, not done; NG, not growth.
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in BL and BCL are shown in Figure 4. BCL cases had a total of
103 chromosome gains (mean 3.772 per case) and 14 losses
(mean 171.2 per case). By contrast, BL patients only showed 40
gains (mean 2.2 7 2 per case) and eight losses. Patients with
BCL showed more gains in 22q, 20q, 9q, 8q, 14q, 15q and 16
than BL cases (Figure 3). Chromosome losses at 13q and 4q were
also more frequent in BCL than in BL patients (Figure 3), but the
differences were not statistically significant. Regarding outcome,
abnormalities on 1q either by CGH or cytogenetics were
associated with a significantly shorter survival in the whole
series (P¼ 0.03) (Figure 4a). In addition, gains on 7q were
associated with a poor outcome (10.5 vs 4.5 months without
abnormalities on 7q, P¼ 0.01). By contrast, no correlation
between the overall number of genomic imbalances assessed by
Figure 3 Summary of the genomic imbalances in 46 patients with BL/BCL. Lines on the left-hand side of the ideogram indicate loss of
chromosomal material; lines on the right-hand side indicate gain of chromosomal material. High-level DNA amplifications are represented as solid
squares. Each line represents a gained or lost region in a single tumor. The numbers on top of each line refer to the patient analyzed (see Table 2):
Cases 1–19 had a diagnosis of BL; cases 20–46 had a diagnosis of BCL.
Table 3 Comparison between BL and BCL in relation to the genomic imbalances
No (%) cases with changes Number of changes Median of changes per case Gains Losses Amplifications
BL (n¼19) 15 (79) 51 2.773 40 8 3
BCL (n¼ 27) 20 (74) 119 4.372 103 14 2
Total BL/BCL (n¼ 46) 35 (76) 170 4.175.1 143 22 5
BL, Burkitt’s lymphoma; BCL, Burkitt’s cell leukemia.
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CGH and survival was found. More than one extranodal
manifestation (P¼ 0.002) and ECOG score 41 (P¼ 0.02) were
shown to be associated with a poor outcome.
Discussion
The increasing number of studies applying CGH to different
entities illustrates the potential of this approach to detect
chromosomal gains and losses in tumor genome. Several studies
have been performed to assess the genomic imbalances in
NHL.19 However, few data concerning CGH in BL have been
reported: to our knowledge, only three BL cell lines and two
patients with BL have been previously reported.20–22
In the present study, 46 BL/BCL patients have been studied
and we have identified chromosomal imbalances by CGH in
76% of them. This incidence of changes in BL/BCL is similar to
the overall frequency reported in follicular lymphoma
(75%),8,22–26 but higher than that reported in other indolent
lymphomas such as HCL, SLL and MZL.6,27,28 However, the
frequency of the alterations in BL/BCL is lower than in
DLBCL10,29 and MCL.7
A similar overall incidence of genomic changes was observed
in patients with BL vs BCL (74 vs 79%). However, some
differences between both diseases BL and BCL were detected.
Thus, the incidence of changes per case was higher in BCL than
in BL (4.372 vs 2.773) (Table 3). Also, three out of the 19
(16%) BL cases had high-level amplifications as compared to
7% of BCL patients. These data indicate that BCL is more
predisposed to carry chromosomal abnormalities than cells from
BL. Gains on chromosome arms 12q, Xq and 22q were the most
frequent single genomic imbalances, suggesting a role as an
early event in the clonal evolution of BL/BCL. In addition, gains
of 20q, 22q, 8q and 9q, as well as losses on 13q were more
frequent in BCL patients (Figure 3). The most frequent genomic
imbalances observed in BL/BCL were gains on 12q without
differences between BL and BCL. Gains of whole chromosome
12 have been detected by CGH in indolent lymphomas,6,28,30
primary mediastinal B-cell lymphoma31 and primary gastro-
intestinal large-cell lymphoma.32 Interestingly, in diffuse large
B-cell lymphoma (DLBCL), the abnormalities of 12q are
uncommon, although they had been reported to be relatively
frequent in transformed DLBCL arising from follicle center cell
lymphoma.27,32–34 Gains on 12q are found in 52% of the
transformed DLBCL and in follicular lymphomas.24,25 In the
present study, the consensus region was located at 12q21–q25,
telomeric to the region reported in blastoid MCL.7 This region
has been frequently gained in mediastinal lymphomas,31
follicular lymphoma24,35 and in primary large B-cell lymphoma
of the gastrointestinal tract.32 All these data suggested a
commonly gained region at 12q for the aggressive NHL,
different to the region observed in SLL or in blastoid MCL.
Abnormalities on chromosome 13 were observed in 30% of
patients with BL/BCL. Losses were more frequent than gains (17
vs 13%) and the losses affected BCL patients more frequently.
Partial or full monosomy of 13 chromosome is usually found in
B-cell chronic lymphocytic leukemia36 and multiple myeloma
patients.37–40 In NHL, the frequencies of losses on 13q ranged
from 4% in follicular lymphomas23 to 49% in MCL.7 Gains on
12q as well as losses on 13q have been reported as most frequent
in cases with aggressive histopathologic features.24 This suggests
a role of these aberrations in later stages of clonal evolution.
Gains on Xq were frequent in the present series, without
differences between BCL and BL patients. Gains of X chromo-
some have been detected usually as a secondary chromosomal
abnormality in NHL.41 The incidence of gains on Xq detected by
CGH in B-cell NHL, ranges from 7% in SMZL to 26% in FL.9,23
By contrast, in DLBCL the incidence of Xq gains reaches more
than 70% of cases of primary mediastinal B-cell lymphoma.42
Moreover, within MCL patients the changes of Xq are more
frequent in that of blastoid MCL variant (40%).7
Five high-level DNA amplifications involving three different
regions have been found in five out of the 46 patients with BCL/
BL. Three cases (two BL and one BCL) displayed 1q amplifica-
tion. In the present series, all the three cases with amp (1q) had a
consensus region at 1q23–q31 and extranodal involvement.
Previous CGH studies have reported high-level amplification of
1q in one case of DLBCL34 and in six cases of extranodal
malignant lymphoma.29
Several reports have correlated the presence of cytogenetic
abnormalities with the outcome of NHL patients. There is
evidence that so-called ‘secondary’ chromosome changes could
play an important role in determining the clinical phenotype of
lymphoid tumours.3,4,24,43 Recent studies have reported on the
impact of CGH on NHL disease-free survival (Table 4) showing
that the increased number of gains or losses were significantly
associated with a short survival.7,9,22,25,29,32,44 In the present
series, we failed to demonstrate an association between the
number of chromosomal changes and the survival of BL/BCL.
However, abnormalities on 1q (gains, high-level amplifications
or translocations) and gains on 7q were associated with a poor
months
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Figure 4 Survival curves of patients with BL. (a) Survival curve of
the whole series according to the presence of changes on 1q assessed
either by cytogenetics or by CGH (normal vs changes; P¼0.03). (b)
Survival curve of the whole series according to the presence of
genomic imbalances by CGH on 7q (P¼0.001). - - - - - -, no changes
on 1q; FF, changes on 1q.
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outcome. Abnormalities on 1q21 detected by cytogenetics and
CGH have been associated with a shorter survival in NHL32,43
and have been reported as an independent cytogenetic risk
factor for patients with centroblastic lymphoma.45 Regarding
gains of chromosome 7, it has been reported that chromosome 7
is probably involved in the progression of NHL.46 All these data
suggest that both abnormalities on 1q and 7q could contribute to
differentiate a subgroup of BL/BCL patients with adverse
prognosis. CGH can detect such genomic aberrations in tumor
tissues and can therefore be used in the context of clinical trials.
In summary, most patients with BCL/BL showed chromosomal
imbalances. The patients with BCL had more chromosomal
abnormalities than patients without BM involvement, particu-
larly gains at 8q, 9q, 14q, 20q and 22q, as well as losses on 13q
and 4q. Concerning outcome, the presence of 1q abnormalities
and gains on 7q were associated with an adverse prognosis.
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